Results 201 to 210 of about 26,789,222 (289)

USP15 Deubiquitinates CARD9 to Downregulate C-Type Lectin Receptor-Mediated Signaling. [PDF]

open access: yesImmunohorizons, 2020
Xu W   +4 more
europepmc   +1 more source

The immunological landscape of the area postrema in neuromyelitis optica spectrum disorders

open access: yesBrain Pathology, EarlyView.
Aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder is characterized by large tissue destructive lesions in medulla, spinal cord, and optic nerves, with only partial recovery from clinical symptoms, and by lesions with very little tissue destruction and mostly complete recovery from clinical symptoms, as seen in the area postrema ...
Qian Yu   +11 more
wiley   +1 more source

Mechanistic insights into the C-type lectin receptor CLEC12A-mediated immune recognition of monosodium urate crystal. [PDF]

open access: yesJ Biol Chem
Tang H   +10 more
europepmc   +1 more source

Protective role of Galectin‐3 in prion disease through regulation of microglial PrPSc uptake

open access: yesBrain Pathology, EarlyView.
Galectin‐3 (Gal3) is induced in reactive microglia during prion disease and promotes microglial uptake of PrPSc. Gal3 deficiency reduces prion sequestration and accelerates disease progression, revealing a protective role for Gal3. Abstract Microglia constitute a major innate defense mechanism against prion infection; however, the molecular pathways ...
Natallia Makarava   +8 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

CD93—An emerging vascular target in cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira   +3 more
wiley   +1 more source

The fight of innate immunity and abnormal cannabinoids against Candida infection

open access: yesBritish Journal of Pharmacology, EarlyView.
Candida species represent the most clinically significant fungal pathogens in humans, with invasive candidiasis carrying a mortality of 30%–40% in critically ill patients despite modern antifungal therapy. The innate immune system – through the coordinated and specific activities of neutrophils, macrophages, NK cells, mast cells and eosinophils ...
Prince Ofori   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy